Thomson I R, Moon M, Hudson R J, Rosenbloom M
Department of Anesthesia, University of Manitoba, St Boniface General Hospital, Winnipeg, Canada.
J Cardiothorac Vasc Anesth. 1999 Feb;13(1):9-14. doi: 10.1016/s1053-0770(99)90165-9.
To search for concentration-related suppression of hemodynamic responsiveness by sufentanil.
Prospective, randomized, double-blind study.
University hospital.
Patients undergoing elective coronary artery bypass grafting (CABG).
Patients were assigned to target effect-site sufentanil concentrations of 1.5 ng/mL (group L; n = 14), 3.0 ng/mL (group M; n = 13), or 4.5 ng/mL (group H; n = 12). Sufentanil was administered by computer-assisted continuous infusion. Isoflurane was used to maintain intraoperative hemodynamics near preoperative values.
Hemodynamics, the electroencephalographic spectral edge (SE95), and end-tidal isoflurane concentration (ET-ISO) were measured every 10 to 30 seconds during the prebypass period. Serum sufentanil concentration was measured at intervals. Prebypass serum sufentanil concentrations were stable, averaging 3.0 +/- 0.7, 5.1 +/- 1.1, and 7.1 +/- 1.3 ng/mL in groups L, M, and H, respectively. The groups did not differ with respect to the speed of induction, intraoperative hemodynamics, incidence of isoflurane use, or isoflurane concentrations required. ET-ISO and serum sufentanil levels were not correlated. Among seven group L patients who did not require isoflurane, the average prebypass serum sufentanil concentration ranged from 1.7 to 3.3 ng/mL.
Sufentanil does not induce concentration-related suppression of hemodynamic responsiveness over the range studied. A stable serum sufentanil concentration of 3.0 +/- 0.7 ng/mL induces the maximal opioid effect and need not be exceeded in patients undergoing CABG. A sufentanil concentration of 1.7 ng/mL provides clinically adequate anesthesia without supplementation in some premedicated patients undergoing CABG.
探寻舒芬太尼对血流动力学反应性的浓度相关抑制作用。
前瞻性、随机、双盲研究。
大学医院。
接受择期冠状动脉旁路移植术(CABG)的患者。
将患者分为三组,目标效应室舒芬太尼浓度分别为1.5 ng/mL(L组;n = 14)、3.0 ng/mL(M组;n = 13)或4.5 ng/mL(H组;n = 12)。舒芬太尼通过计算机辅助持续输注给药。异氟烷用于维持术中血流动力学接近术前值。
在体外循环前阶段,每10至30秒测量一次血流动力学、脑电图频谱边缘(SE95)和呼气末异氟烷浓度(ET-ISO)。定期测量血清舒芬太尼浓度。体外循环前血清舒芬太尼浓度稳定,L组、M组和H组的平均值分别为3.0±0.7、5.1±1.1和7.1±1.3 ng/mL。三组在诱导速度、术中血流动力学、异氟烷使用发生率或所需异氟烷浓度方面无差异。ET-ISO与血清舒芬太尼水平不相关。在七名不需要异氟烷的L组患者中,体外循环前血清舒芬太尼浓度平均范围为1.7至3.3 ng/mL。
在所研究的浓度范围内,舒芬太尼不会引起血流动力学反应性的浓度相关抑制。3.0±0.7 ng/mL的稳定血清舒芬太尼浓度可诱导最大的阿片类药物效应,在接受CABG的患者中无需超过此浓度。1.7 ng/mL的舒芬太尼浓度可为一些接受CABG的术前用药患者提供临床充分的麻醉,无需补充其他药物。